Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium

Q. Jackie Cao, Thomas Belbin, Nicholas Socci, Raluca Balan, Michael B. Prystowsky, Geoffrey J. Childs, Joan G. Jones

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Endometrial carcinomas are classified by their morphology into two major subtypes. Endometrioid carcinomas (type I) are generally estrogen dependent, well-differentiated, superficially invasive, and have a good outcome. Serous carcinomas (type II) are hormone independent, frequently deeply invasive and widely metastatic, and have a poor prognosis. Microarray technology and analysis allows us to determine if the global gene expression profiles of these two subtypes correlate with their morphologic phenotype. Fresh tissue from 18 endometrial carcinomas was studied: 7 well-, 2 moderately, and one poorly differentiated endometrioid, 4 serous carcinomas, and 4 high-grade mixed endometrioid-serous carcinomas. Labeled cDNA probes were synthesized (Cy5 for tumor, Cy3 for reference) and applied to microarrays containing 18,098 cDNA clones or ESTs. A pool of equal amounts of total RNA from each tumor served as the reference RNA. By unsupervised cluster analysis, the endometrioid carcinomas clustered together and were separate from the serous carcinomas. The high-grade mixed carcinomas clustered with the serous carcinomas. Using a statistical algorithm based on gene expression pattern and conducting a supervised analysis of the two defined groups, we have identified 315 genes that statistically differentiate type I from type II endometrial carcinomas. In addition to corroborating the predicted overexpression of known markers (e.g., ras and catenin in endometrioid carcinomas), the cDNA microarray technique has revealed novel alterations in gene expression relevant to cell cycle, cell adhesion, signal transduction, apoptosis, and tumor progression not previously implicated in endometrial carcinomas. For serous carcinomas, these include aldolase, desmoplakin, integrin-linked kinase, PKC, and metallopeptidase. In conclusion, the gene expression profiles of type I and type II endometrial carcinomas are different. Refinement of these profiles will permit more accurate diagnostic tumor classification and the development of prognosis assays.

Original languageEnglish (US)
Pages (from-to)321-329
Number of pages9
JournalInternational Journal of Gynecological Pathology
Volume23
Issue number4
DOIs
StatePublished - Oct 2004

Fingerprint

Endometrioid Carcinoma
Endometrial Neoplasms
Oligonucleotide Array Sequence Analysis
Transcriptome
Carcinoma
Neoplasms
Complementary DNA
Desmoplakins
RNA
Gene Expression
Catenins
Fructose-Bisphosphate Aldolase
Expressed Sequence Tags
Metalloproteases
Microarray Analysis
Cell Adhesion
Cluster Analysis
Signal Transduction
Cell Cycle
Estrogens

Keywords

  • cDNA microarrays
  • Endometrial carcinoma
  • Endometrioid
  • Serous

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Obstetrics and Gynecology

Cite this

Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. / Cao, Q. Jackie; Belbin, Thomas; Socci, Nicholas; Balan, Raluca; Prystowsky, Michael B.; Childs, Geoffrey J.; Jones, Joan G.

In: International Journal of Gynecological Pathology, Vol. 23, No. 4, 10.2004, p. 321-329.

Research output: Contribution to journalArticle

@article{aeb18f875f00437492a750fba6f7c5e9,
title = "Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium",
abstract = "Endometrial carcinomas are classified by their morphology into two major subtypes. Endometrioid carcinomas (type I) are generally estrogen dependent, well-differentiated, superficially invasive, and have a good outcome. Serous carcinomas (type II) are hormone independent, frequently deeply invasive and widely metastatic, and have a poor prognosis. Microarray technology and analysis allows us to determine if the global gene expression profiles of these two subtypes correlate with their morphologic phenotype. Fresh tissue from 18 endometrial carcinomas was studied: 7 well-, 2 moderately, and one poorly differentiated endometrioid, 4 serous carcinomas, and 4 high-grade mixed endometrioid-serous carcinomas. Labeled cDNA probes were synthesized (Cy5 for tumor, Cy3 for reference) and applied to microarrays containing 18,098 cDNA clones or ESTs. A pool of equal amounts of total RNA from each tumor served as the reference RNA. By unsupervised cluster analysis, the endometrioid carcinomas clustered together and were separate from the serous carcinomas. The high-grade mixed carcinomas clustered with the serous carcinomas. Using a statistical algorithm based on gene expression pattern and conducting a supervised analysis of the two defined groups, we have identified 315 genes that statistically differentiate type I from type II endometrial carcinomas. In addition to corroborating the predicted overexpression of known markers (e.g., ras and catenin in endometrioid carcinomas), the cDNA microarray technique has revealed novel alterations in gene expression relevant to cell cycle, cell adhesion, signal transduction, apoptosis, and tumor progression not previously implicated in endometrial carcinomas. For serous carcinomas, these include aldolase, desmoplakin, integrin-linked kinase, PKC, and metallopeptidase. In conclusion, the gene expression profiles of type I and type II endometrial carcinomas are different. Refinement of these profiles will permit more accurate diagnostic tumor classification and the development of prognosis assays.",
keywords = "cDNA microarrays, Endometrial carcinoma, Endometrioid, Serous",
author = "Cao, {Q. Jackie} and Thomas Belbin and Nicholas Socci and Raluca Balan and Prystowsky, {Michael B.} and Childs, {Geoffrey J.} and Jones, {Joan G.}",
year = "2004",
month = "10",
doi = "10.1097/01.pgp.0000139646.32997.3a",
language = "English (US)",
volume = "23",
pages = "321--329",
journal = "International Journal of Gynecological Pathology",
issn = "0277-1691",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium

AU - Cao, Q. Jackie

AU - Belbin, Thomas

AU - Socci, Nicholas

AU - Balan, Raluca

AU - Prystowsky, Michael B.

AU - Childs, Geoffrey J.

AU - Jones, Joan G.

PY - 2004/10

Y1 - 2004/10

N2 - Endometrial carcinomas are classified by their morphology into two major subtypes. Endometrioid carcinomas (type I) are generally estrogen dependent, well-differentiated, superficially invasive, and have a good outcome. Serous carcinomas (type II) are hormone independent, frequently deeply invasive and widely metastatic, and have a poor prognosis. Microarray technology and analysis allows us to determine if the global gene expression profiles of these two subtypes correlate with their morphologic phenotype. Fresh tissue from 18 endometrial carcinomas was studied: 7 well-, 2 moderately, and one poorly differentiated endometrioid, 4 serous carcinomas, and 4 high-grade mixed endometrioid-serous carcinomas. Labeled cDNA probes were synthesized (Cy5 for tumor, Cy3 for reference) and applied to microarrays containing 18,098 cDNA clones or ESTs. A pool of equal amounts of total RNA from each tumor served as the reference RNA. By unsupervised cluster analysis, the endometrioid carcinomas clustered together and were separate from the serous carcinomas. The high-grade mixed carcinomas clustered with the serous carcinomas. Using a statistical algorithm based on gene expression pattern and conducting a supervised analysis of the two defined groups, we have identified 315 genes that statistically differentiate type I from type II endometrial carcinomas. In addition to corroborating the predicted overexpression of known markers (e.g., ras and catenin in endometrioid carcinomas), the cDNA microarray technique has revealed novel alterations in gene expression relevant to cell cycle, cell adhesion, signal transduction, apoptosis, and tumor progression not previously implicated in endometrial carcinomas. For serous carcinomas, these include aldolase, desmoplakin, integrin-linked kinase, PKC, and metallopeptidase. In conclusion, the gene expression profiles of type I and type II endometrial carcinomas are different. Refinement of these profiles will permit more accurate diagnostic tumor classification and the development of prognosis assays.

AB - Endometrial carcinomas are classified by their morphology into two major subtypes. Endometrioid carcinomas (type I) are generally estrogen dependent, well-differentiated, superficially invasive, and have a good outcome. Serous carcinomas (type II) are hormone independent, frequently deeply invasive and widely metastatic, and have a poor prognosis. Microarray technology and analysis allows us to determine if the global gene expression profiles of these two subtypes correlate with their morphologic phenotype. Fresh tissue from 18 endometrial carcinomas was studied: 7 well-, 2 moderately, and one poorly differentiated endometrioid, 4 serous carcinomas, and 4 high-grade mixed endometrioid-serous carcinomas. Labeled cDNA probes were synthesized (Cy5 for tumor, Cy3 for reference) and applied to microarrays containing 18,098 cDNA clones or ESTs. A pool of equal amounts of total RNA from each tumor served as the reference RNA. By unsupervised cluster analysis, the endometrioid carcinomas clustered together and were separate from the serous carcinomas. The high-grade mixed carcinomas clustered with the serous carcinomas. Using a statistical algorithm based on gene expression pattern and conducting a supervised analysis of the two defined groups, we have identified 315 genes that statistically differentiate type I from type II endometrial carcinomas. In addition to corroborating the predicted overexpression of known markers (e.g., ras and catenin in endometrioid carcinomas), the cDNA microarray technique has revealed novel alterations in gene expression relevant to cell cycle, cell adhesion, signal transduction, apoptosis, and tumor progression not previously implicated in endometrial carcinomas. For serous carcinomas, these include aldolase, desmoplakin, integrin-linked kinase, PKC, and metallopeptidase. In conclusion, the gene expression profiles of type I and type II endometrial carcinomas are different. Refinement of these profiles will permit more accurate diagnostic tumor classification and the development of prognosis assays.

KW - cDNA microarrays

KW - Endometrial carcinoma

KW - Endometrioid

KW - Serous

UR - http://www.scopus.com/inward/record.url?scp=4644222599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644222599&partnerID=8YFLogxK

U2 - 10.1097/01.pgp.0000139646.32997.3a

DO - 10.1097/01.pgp.0000139646.32997.3a

M3 - Article

C2 - 15381901

AN - SCOPUS:4644222599

VL - 23

SP - 321

EP - 329

JO - International Journal of Gynecological Pathology

JF - International Journal of Gynecological Pathology

SN - 0277-1691

IS - 4

ER -